SUFU (Suppressor of fused homolog) variants and mutations
SUFU (also known as Suppressor of fused homolog) is a human protein-coding gene encoding a suppressor of fused homolog protein. It restrains GLI transcription factors and thereby keeps Hedgehog signaling off when pathway activation is absent. Germline loss-of-function variants predispose particularly to infant desmoplastic medulloblastoma and can also cause developmental Hedgehog-pathway phenotypes. This analysis covers 1,156 SUFU variants and mutations. Of these, 70% have computational variant effect predictions. Disease context includes medulloblastoma, nevoid basal cell carcinoma syndrome, and Joubert syndrome 32. Example SUFU variants include M1?, M1K, and A2E.
Variant analysis overview
- Gene: SUFU
- Protein: Suppressor of fused homolog
- UniProt accession: Q9UMX1
- Organism: Homo sapiens
- Variants analyzed: 1156
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 980 unspecified-consequence records; 54 missense variants; 94 synonymous variants; 2 stop-gained variants; 13 frameshift variants; 6 in-frame deletions; 4 splice-region variants; 3 substitution
- Prediction scores: 805 variants have prediction scores (70% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: medulloblastoma, nevoid basal cell carcinoma syndrome, Joubert syndrome 32, familial meningioma, Joubert syndrome, hereditary neoplastic syndrome, Inherited cancer-predisposing syndrome, meningioma, neurodevelopmental disorder, skin basal cell carcinoma, lung carcinoma, esophageal adenocarcinoma.
Protein structure and variant hotspots
- Protein features: 7 post-translational modification sites.
- PTM context: 18 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable SUFU variants
Examples include M1?, M1K, A2E, A2V, A2S, A2A, E3A, E3D. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, rs1443773793, NCI-TCGA Cosmic COSV6401, MetaLR 0.20, MetaSVM -0.79, Variant assessed as somatic; high impact.
- M1K (p.Met1Lys), rs2544829669, ClinGen CA377885976, ClinVar RCV003306784, Likely pathogenic, Hereditary cancer-predisposing syndrome
- A2E (p.Ala2Glu), gnomAD rs1589969719, REVEL 0.09, CADD 18.10, Uncertain significance
- A2V (p.Ala2Val), rs1589969719, ClinGen CA377886005, ClinVar RCV000824588, gnomAD rs1589969719, REVEL 0.07, CADD 22.50, Uncertain significance, Gorlin syndrome; Medulloblastoma
- A2S (p.Ala2Ser), gnomAD 10-102504156-G-T, REVEL 0.07, CADD 22.30
- A2A (p.Ala2Ala), rs746555296, gnomAD 10-102504158-G-A, CADD 14.50
- E3A (p.Glu3Ala), ExAC rs757097388, gnomAD rs757097388, Uncertain significance
- E3D (p.Glu3Asp), 1000Genomes rs561651427, ExAC rs561651427, TOPMed rs561651427, gnomAD rs561651427, REVEL 0.10, CADD 22.20, Uncertain significance, Hereditary cancer-predisposing syndrome; Familial meningioma; Basal cell nevus s
- E3G (p.Glu3Gly), rs757097388, ClinGen CA5667574, ClinVar RCV000694830, ExAC rs757097388, REVEL 0.09, CADD 25.00, Uncertain significance, Gorlin syndrome; Medulloblastoma
- E3V (p.Glu3Val), ExAC rs757097388, gnomAD rs757097388, Uncertain significance
- E3* (p.Glu3Ter), gnomAD 10-102504159-G-T, CADD 38.00
- E3E (p.Glu3Glu), rs561651427, gnomAD 10-102504161-G-A, CADD 13.40
- L4R (p.Leu4Arg), rs1297525468, ClinGen CA377886058, ClinVar RCV002347186, ClinVar RCV003776100, REVEL 0.17, CADD 24.40, Uncertain significance, Gorlin syndrome; Medulloblastoma; not specified
- L4M (p.Leu4Met), gnomAD 10-102504162-C-A, REVEL 0.09, CADD 22.80
- L4P (p.Leu4Pro), gnomAD 10-102504163-T-C, REVEL 0.22, CADD 24.60
- L4L (p.Leu4Leu), rs189234140, gnomAD 10-102504164-G-A, CADD 13.50
- R5W (p.Arg5Trp), rs948353979, ClinGen CA212238071, cosmic curated COSV64015, ClinVar RCV001228839, REVEL 0.27, CADD 28.10, Uncertain significance, Hereditary cancer-predisposing syndrome; Familial meningioma; Gorlin syndrome
- R5R (p.Arg5Arg), gnomAD 10-102504165-C-A, CADD 14.40
- P6R (p.Pro6Arg), rs2135597134, ClinGen CA377886100, ClinVar RCV001363131, Ensembl rs2135597134, AlphaMissense 0.14, MetaLR 0.27, Uncertain significance, Medulloblastoma; Gorlin syndrome
- P6S (p.Pro6Ser), rs2062288467, ClinGen CA377886092, ClinVar RCV001325209, ClinVar RCV002412042, REVEL 0.18, CADD 22.30, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P6T (p.Pro6Thr), gnomAD 10-102504168-C-A, REVEL 0.20, CADD 21.90
- P6P (p.Pro6Pro), gnomAD 10-102504170-T-C, CADD 15.90
- S7G (p.Ser7Gly), rs2062288510, ClinGen CA377886106, ClinVar RCV001874556, ClinVar RCV006287504, REVEL 0.09, CADD 24.00, Conflicting interpretations, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- S7N (p.Ser7Asn), gnomAD rs1449152687, REVEL 0.14, CADD 24.00, Uncertain significance, Gorlin syndrome; Medulloblastoma
- S7R (p.Ser7Arg), rs2135597167, ClinGen CA377886119, ClinVar RCV002842542, ClinVar RCV005288826, REVEL 0.04, CADD 22.50, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- S7S (p.Ser7Ser), gnomAD 10-102504173-C-T, CADD 13.70
- G8C (p.Gly8Cys), rs769696737, ClinGen CA377886123, ClinVar RCV000688921, ClinVar RCV005492862, AlphaMissense 0.10, MetaLR 0.15, Uncertain significance, Hereditary cancer-predisposing syndrome; Medulloblastoma; Gorlin syndrome
- G8R (p.Gly8Arg), rs2544829884, ClinGen CA2825001676, ClinVar RCV004522041, Likely pathogenic
- G8S (p.Gly8Ser), ExAC rs769696737, Uncertain significance
- G8G (p.Gly8Gly), rs1291941856, gnomAD 10-102504176-C-T, CADD 14.20
- A9D (p.Ala9Asp), rs775491374, ClinGen CA5667578, ClinVar RCV001218056, ClinVar RCV002429927, REVEL 0.13, CADD 22.40, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A9G (p.Ala9Gly), ExAC rs775491374, TOPMed rs775491374, gnomAD rs775491374, Likely benign
- A9P (p.Ala9Pro), TOPMed rs1457645233, gnomAD rs1457645233
- A9T (p.Ala9Thr), TOPMed rs1457645233, gnomAD rs1457645233, REVEL 0.12, CADD 23.10
- A9V (p.Ala9Val), rs775491374, ClinGen CA377886134, ClinVar RCV000628510, ClinVar RCV001016349, REVEL 0.11, CADD 22.30, Conflicting interpretations, Gorlin syndrome; Medulloblastoma; Familial meningioma
- A9A (p.Ala9Ala), rs1244167364, gnomAD 10-102504179-C-T, CADD 14.70
- P10A (p.Pro10Ala), rs975936230, ClinGen CA377886145, ClinVar RCV003805860, AlphaMissense 0.07, MetaLR 0.21, Uncertain significance, Gorlin syndrome; Medulloblastoma
- P10S (p.Pro10Ser), rs975936230, ClinGen CA212238074, ClinVar RCV001364016, Ensembl rs975936230, REVEL 0.09, AlphaMissense 0.07, Uncertain significance, Medulloblastoma; Gorlin syndrome
- P10T (p.Pro10Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P10H (p.Pro10His), gnomAD 10-102504181-C-A, REVEL 0.17, CADD 23.30
- P10P (p.Pro10Pro), rs1315277679, gnomAD 10-102504182-C-T, CADD 12.80
- G11A (p.Gly11Ala), gnomAD rs1227379293, REVEL 0.15, AlphaMissense 0.07, Uncertain significance
- G11D (p.Gly11Asp), rs1227379293, ClinGen CA377886163, cosmic curated COSV64016, ClinVar RCV000707040, REVEL 0.15, AlphaMissense 0.07, Uncertain significance, Gorlin syndrome; Medulloblastoma; not provided
- G11R (p.Gly11Arg), rs1322807658, ClinGen CA377886157, ClinVar RCV002256837, ClinVar RCV003238000, REVEL 0.14, CADD 23.50, Conflicting interpretations, Familial meningioma; Basal cell nevus syndrome 2; Joubert syndrome 32
- G11S (p.Gly11Ser), rs1322807658, ClinGen CA377886154, ClinVar RCV003795011, gnomAD rs1322807658, REVEL 0.15, CADD 22.80, Uncertain significance, Gorlin syndrome; Medulloblastoma
- G11V (p.Gly11Val), rs1227379293, ClinGen CA377886160, ClinVar RCV003360698, gnomAD rs1227379293, AlphaMissense 0.07, MetaLR 0.27, Uncertain significance, Hereditary cancer-predisposing syndrome
- G11G (p.Gly11Gly), rs12780566, gnomAD 10-102504185-C-G, CADD 13.10
- P12H (p.Pro12His), rs2544830107, ClinGen CA377886189, ClinVar RCV002346596, Uncertain significance, Hereditary cancer-predisposing syndrome
- P12R (p.Pro12Arg), rs2544830107, ClinGen CA377886184, ClinVar RCV004522046, Uncertain significance, Hereditary cancer-predisposing syndrome
- P12S (p.Pro12Ser), rs2544830097, ClinGen CA377886176, ClinVar RCV003782814, REVEL 0.10, CADD 18.80, Uncertain significance, Gorlin syndrome; Medulloblastoma
- P12T (p.Pro12Thr), rs2544830097, ClinGen CA377886172, ClinVar RCV003138858, Uncertain significance, not provided
- P12L (p.Pro12Leu), gnomAD 10-102504187-C-T, REVEL 0.14, CADD 18.80
- P12P (p.Pro12Pro), gnomAD 10-102504188-C-T, CADD 11.70
- T13A (p.Thr13Ala), rs1456048322, ClinGen CA377886200, ClinVar RCV003177382, AlphaMissense 0.05, MetaLR 0.06, Likely benign, Hereditary cancer-predisposing syndrome
- T13I (p.Thr13Ile), rs768935165, ClinGen CA5667581, ClinVar RCV001021386, ClinVar RCV001054304, REVEL 0.07, CADD 19.00, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- T13N (p.Thr13Asn), ExAC rs768935165, TOPMed rs768935165, gnomAD rs768935165, Uncertain significance
- T13P (p.Thr13Pro), rs1456048322, ClinGen CA377886198, cosmic curated COSV64015, ClinVar RCV000988446, REVEL 0.14, AlphaMissense 0.05, Conflicting interpretations, Gorlin syndrome; Medulloblastoma; Joubert syndrome 32
- T13S (p.Thr13Ser), rs1456048322, ClinGen CA377886204, ClinVar RCV002363950, REVEL 0.09, CADD 15.40, Uncertain significance, Hereditary cancer-predisposing syndrome
- T13W (p.Thr13Trp), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- T13H (p.Thr13His), gnomAD 10-102504182-C-CG, CADD 25.00
- p.Thr13 Ala14del, rs1589969829, gnomAD 10-102504188-CACC, CADD 20.00
- T13T (p.Thr13Thr), gnomAD 10-102504191-C-A, CADD 9.53
- A14P (p.Ala14Pro), cosmic curated COSV64015, gnomAD rs1460606381, REVEL 0.11, AlphaMissense 0.08, Uncertain significance, Hereditary cancer-predisposing syndrome
- A14T (p.Ala14Thr), rs1460606381, ClinGen CA377886217, ClinVar RCV003310401, ClinVar RCV006561338, AlphaMissense 0.08, MetaLR 0.19, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- A14del (p.Ala14del), rs1238391585, gnomAD 10-102504191-CGCG, CADD 20.30
- A14R (p.Ala14Arg), gnomAD 10-102504191-CG-C, CADD 27.50
- A14E (p.Ala14Glu), gnomAD 10-102504193-C-A, REVEL 0.11, CADD 21.00
- A14A (p.Ala14Ala), rs1179829804, gnomAD 10-102504194-G-C, CADD 13.60
- P15A (p.Pro15Ala), rs761921681, ClinGen CA377886232, ClinVar RCV001366244, ClinVar RCV002329374, AlphaMissense 0.07, MetaLR 0.10, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- P15L (p.Pro15Leu), rs28942088, ClinGen CA116361, ClinVar RCV000003750, ClinVar RCV004772827, AlphaMissense 0.09, MetaLR 0.13, Uncertain significance, not provided
- P15S (p.Pro15Ser), rs761921681, ClinGen CA377886234, ClinVar RCV002333729, ExAC rs761921681, REVEL 0.07, AlphaMissense 0.07, Uncertain significance, Hereditary cancer-predisposing syndrome
- P15T (p.Pro15Thr), rs761921681, ClinGen CA5667582, cosmic curated COSV10592, ClinVar RCV000535620, REVEL 0.07, AlphaMissense 0.07, Conflicting interpretations, Joubert syndrome 32; Gorlin syndrome; Medulloblastoma
- P15H (p.Pro15His), gnomAD 10-102504196-C-A, REVEL 0.11, CADD 22.10
- P15P (p.Pro15Pro), gnomAD 10-102504197-C-A, CADD 14.10
- P16A (p.Pro16Ala), rs978312925, ClinGen CA377886246, ClinVar RCV002938160, AlphaMissense 0.07, MetaLR 0.13, Uncertain significance, Gorlin syndrome; Medulloblastoma
- P16L (p.Pro16Leu), rs1690152705, ClinGen CA377886249, ClinVar RCV002605568, ClinVar RCV003375653, REVEL 0.12, CADD 22.60, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- P16S (p.Pro16Ser), TOPMed rs978312925, gnomAD rs978312925, REVEL 0.10, AlphaMissense 0.07, Uncertain significance
- P16T (p.Pro16Thr), rs978312925, ClinGen CA212238099, ClinVar RCV001210588, ClinVar RCV001574638, REVEL 0.11, AlphaMissense 0.07, Uncertain significance, not provided; Gorlin syndrome; Medulloblastoma
- P16R (p.Pro16Arg), gnomAD 10-102504192-G-GC, CADD 28.30
- P16Q (p.Pro16Gln), gnomAD 10-102504199-C-A, REVEL 0.12, CADD 22.20
- P16P (p.Pro16Pro), rs1467238395, gnomAD 10-102504200-G-C, CADD 12.50
- A17D (p.Ala17Asp), 1000Genomes rs12780580, ExAC rs12780580, TOPMed rs12780580, gnomAD rs12780580, Uncertain significance, not provided
- A17G (p.Ala17Gly), rs12780580, ClinGen CA377886260, ClinVar RCV004522054, REVEL 0.11, CADD 22.40, Uncertain significance, Hereditary cancer-predisposing syndrome
- A17P (p.Ala17Pro), rs1332143456, ClinGen CA377886254, ClinVar RCV002343020, ClinVar RCV005213686, REVEL 0.12, CADD 22.70, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- A17S (p.Ala17Ser), NCI-TCGA TCGA novel, REVEL 0.08, CADD 21.70, Variant assessed as somatic; moderate impact.
- A17V (p.Ala17Val), rs12780580, ClinGen CA5667584, cosmic curated COSV64016, ClinVar RCV000475558, REVEL 0.11, CADD 22.70, Conflicting interpretations, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A17T (p.Ala17Thr), gnomAD 10-102504201-G-A, REVEL 0.07, CADD 22.60
- A17A (p.Ala17Ala), rs1450764224, gnomAD 10-102504203-C-T, CADD 14.80
- P18A (p.Pro18Ala), rs1589969896, ClinGen CA377886267, ClinVar RCV003177390, AlphaMissense 0.06, MetaLR 0.08, Uncertain significance, Hereditary cancer-predisposing syndrome
- P18L (p.Pro18Leu), rs1489443369, ClinGen CA377886273, ClinVar RCV003176337, ClinVar RCV003778944, AlphaMissense 0.13, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- P18R (p.Pro18Arg), rs1489443369, ClinGen CA377886271, ClinVar RCV001925163, ClinVar RCV002343997, REVEL 0.10, AlphaMissense 0.13, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- P18S (p.Pro18Ser), Ensembl rs1589969896, REVEL 0.08, AlphaMissense 0.06
- P18T (p.Pro18Thr), rs1589969896, ClinGen CA377886265, ClinVar RCV002304498, REVEL 0.06, AlphaMissense 0.06, Uncertain significance, Gorlin syndrome; Medulloblastoma
- p.Pro18 Ala25del, rs2062289607, gnomAD 10-102504191-CGCG, CADD 20.50
- P18P (p.Pro18Pro), gnomAD 10-102504206-T-A, CADD 13.40
- G19A (p.Gly19Ala), Ensembl rs1589969913, Uncertain significance
- G19D (p.Gly19Asp), rs1589969913, ClinGen CA377886281, ClinVar RCV001024427, ClinVar RCV001069906, AlphaMissense 0.23, MetaLR 0.13, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- G19R (p.Gly19Arg), TOPMed rs1207697890, gnomAD rs1207697890, REVEL 0.13, CADD 22.20, Uncertain significance
- G19S (p.Gly19Ser), rs1207697890, ClinGen CA377886277, ClinVar RCV000628509, ClinVar RCV002343186, REVEL 0.09, CADD 20.00, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- G19V (p.Gly19Val), rs1589969913, ClinGen CA377886286, ClinVar RCV003464659, UniProt VAR 080418, AlphaMissense 0.23, MetaLR 0.13, Uncertain significance, Familial meningioma
- G19C (p.Gly19Cys), gnomAD 10-102504205-CTGG, CADD 28.90
- G19del (p.Gly19del), rs2135597646, gnomAD 10-102504205-CTGG, CADD 19.50
- G19P (p.Gly19Pro), rs2135597658, gnomAD 10-102504205-CTGG, CADD 31.00
- P20A (p.Pro20Ala), rs936379170, ClinGen CA212238100, ClinVar RCV003035878, ClinVar RCV003459715, AlphaMissense 0.07, MetaLR 0.13, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- P20L (p.Pro20Leu), rs2544830551, ClinGen CA377886296, ClinVar RCV003787810, Uncertain significance, Gorlin syndrome; Medulloblastoma
- P20R (p.Pro20Arg), rs2544830551, ClinGen CA377886294, ClinVar RCV003464660, ClinVar RCV004673897, REVEL 0.09, CADD 22.90, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P20S (p.Pro20Ser), gnomAD rs936379170, REVEL 0.06, AlphaMissense 0.07, Uncertain significance
- P20P (p.Pro20Pro), rs1589969926, gnomAD 10-102504212-G-C, CADD 8.43
- T21A (p.Thr21Ala), Ensembl rs2135597746, REVEL 0.09, CADD 15.60
- T21I (p.Thr21Ile), rs2544830615, ClinGen CA377886306, ClinVar RCV003794398, Uncertain significance, Medulloblastoma; Gorlin syndrome
- T21P (p.Thr21Pro), cosmic curated COSV10943, Ensembl rs2135597746, REVEL 0.08, CADD 18.90
- T21S (p.Thr21Ser), Ensembl rs2135597746, Likely benign, Hereditary cancer-predisposing syndrome
- p.Thr21 Pro23del, gnomAD 10-102504208-GCCC, CADD 21.30
- T21N (p.Thr21Asn), gnomAD 10-102504214-C-A, REVEL 0.08, CADD 15.50
- T21T (p.Thr21Thr), rs1589969931, gnomAD 10-102504215-T-C, CADD 14.10
- A22D (p.Ala22Asp), rs761240106, ClinGen CA377886325, ClinVar RCV001308204, ClinVar RCV002366155, REVEL 0.26, CADD 23.90, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A22G (p.Ala22Gly), rs761240106, ClinGen CA5667586, ClinVar RCV000474319, ClinVar RCV002365622, REVEL 0.13, CADD 21.90, Conflicting interpretations, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A22P (p.Ala22Pro), rs1564654422, ClinGen CA377886318, ClinVar RCV001349569, ClinVar RCV002368147, REVEL 0.19, CADD 24.80, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A22S (p.Ala22Ser), rs1564654422, ClinGen CA377886319, ClinVar RCV002364136, REVEL 0.13, CADD 22.70, Uncertain significance, Hereditary cancer-predisposing syndrome
- A22V (p.Ala22Val), rs761240106, ClinGen CA212238105, ClinVar RCV000795767, ClinVar RCV004027536, REVEL 0.17, CADD 23.60, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- A22A (p.Ala22Ala), rs1265496966, gnomAD 10-102504218-C-T, CADD 13.80
- P23A (p.Pro23Ala), rs766666529, ClinGen CA377886330, ClinVar RCV001316062, ClinVar RCV004951510, AlphaMissense 0.06, MetaLR 0.11, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P23L (p.Pro23Leu), rs2062290972, ClinGen CA377886338, ClinVar RCV001337733, ClinVar RCV002377432, REVEL 0.10, AlphaMissense 0.10, Conflicting interpretations, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- P23R (p.Pro23Arg), rs2062290972, ClinGen CA377886336, ClinVar RCV003781915, ClinVar RCV004573314, AlphaMissense 0.10, MetaLR 0.17, Uncertain significance, Medulloblastoma; Gorlin syndrome; Familial meningioma
- P23S (p.Pro23Ser), rs766666529, ClinGen CA5667587, ClinVar RCV000574522, ClinVar RCV000821320, REVEL 0.06, AlphaMissense 0.06, Conflicting interpretations, Medulloblastoma; Gorlin syndrome; not provided
- P23P (p.Pro23Pro), rs1320688671, gnomAD 10-102504221-C-T, CADD 10.30
- P24A (p.Pro24Ala), rs1219870817, ClinGen CA377886343, ClinVar RCV001026035, ClinVar RCV001063730, AlphaMissense 0.05, MetaLR 0.13, Uncertain significance, Hereditary cancer-predisposing syndrome; Familial meningioma; Gorlin syndrome
- P24L (p.Pro24Leu), rs754218597, ClinGen CA5667588, ClinVar RCV003341958, ClinVar RCV003777481, REVEL 0.06, CADD 22.30, Uncertain significance, Hereditary cancer-predisposing syndrome; Medulloblastoma; Gorlin syndrome
- P24Q (p.Pro24Gln), rs754218597, ClinGen CA377886345, ClinVar RCV001026147, ClinVar RCV001374122, REVEL 0.06, CADD 19.80, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- P24S (p.Pro24Ser), rs1219870817, NCI-TCGA TCGA novel, ClinGen CA377886342, ClinVar RCV001242490, AlphaMissense 0.05, MetaLR 0.13, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P24T (p.Pro24Thr), rs1219870817, ClinGen CA377886340, cosmic curated COSV64016, ClinVar RCV003787629, REVEL 0.08, AlphaMissense 0.05, Uncertain significance, Medulloblastoma; Gorlin syndrome; not specified
- P24R (p.Pro24Arg), rs587776579, gnomAD 10-102504216-GC-G, CADD 26.60
- P24P (p.Pro24Pro), rs1322344970, gnomAD 10-102504224-G-C, CADD 13.00
- A25P (p.Ala25Pro), Ensembl rs2135597901, Uncertain significance
- A25T (p.Ala25Thr), rs2135597901, ClinGen CA377886349, ClinVar RCV002005708, Ensembl rs2135597901, AlphaMissense 0.08, MetaLR 0.12, Uncertain significance, Medulloblastoma; Gorlin syndrome
- A25V (p.Ala25Val), rs2062291323, ClinGen CA377886358, ClinVar RCV001344752, ClinVar RCV002395755, AlphaMissense 0.10, MetaLR 0.16, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A25G (p.Ala25Gly), rs587776579, gnomAD 10-102504216-G-GC, CADD 32.00
- F26I (p.Phe26Ile), rs1589970016, ClinGen CA377886361, ClinVar RCV002400594, AlphaMissense 0.63, MetaLR 0.17, Uncertain significance, Hereditary cancer-predisposing syndrome
- F26L (p.Phe26Leu), Ensembl rs2135597954, REVEL 0.23, AlphaMissense 0.63, Likely benign
- F26S (p.Phe26Ser), Ensembl rs2135597944
- A27D (p.Ala27Asp), gnomAD rs1664857380, REVEL 0.07, AlphaMissense 0.45, Uncertain significance
- A27P (p.Ala27Pro), Ensembl rs2062291537, Uncertain significance
- A27S (p.Ala27Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A27T (p.Ala27Thr), rs2062291537, ClinGen CA377886376, ClinVar RCV001213520, ClinVar RCV002418731, REVEL 0.05, CADD 22.40, Uncertain significance, Hereditary cancer-predisposing syndrome; Medulloblastoma; Gorlin syndrome
- A27V (p.Ala27Val), rs1664857380, ClinGen CA377886386, ClinVar RCV001999120, gnomAD rs1664857380, AlphaMissense 0.45, MetaLR 0.15, Uncertain significance, Medulloblastoma; Gorlin syndrome
- S28* (p.Ser28Ter), ExAC rs758001170, TOPMed rs758001170, gnomAD rs758001170, Uncertain significance
- S28A (p.Ser28Ala), rs2544830892, ClinGen CA377886392, ClinVar RCV002574855, Uncertain significance, Medulloblastoma; Gorlin syndrome
- S28L (p.Ser28Leu), rs758001170, ClinGen CA5667589, ClinVar RCV002434899, ClinVar RCV004572385, REVEL 0.09, CADD 22.10, Uncertain significance, Hereditary cancer-predisposing syndrome; Familial meningioma
- S28S (p.Ser28Ser), rs376752468, gnomAD 10-102504236-G-T, CADD 8.46
- L29R (p.Leu29Arg), rs2062291773, ClinGen CA377886411, ClinVar RCV001046021, ClinVar RCV002372793, REVEL 0.30, CADD 26.10, Uncertain significance, Familial meningioma; Medulloblastoma; Gorlin syndrome
- L29L (p.Leu29Leu), rs2135598027, gnomAD 10-102504239-C-T, CADD 13.60
- F30L (p.Phe30Leu), Ensembl rs2135598035, REVEL 0.41, CADD 22.90, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- F30S (p.Phe30Ser), Ensembl rs2135598053
- F30C (p.Phe30Cys), gnomAD 10-102504241-T-G, REVEL 0.57, CADD 24.30
- F30F (p.Phe30Phe), rs1589970035, gnomAD 10-102504242-T-C, CADD 10.40
- P31A (p.Pro31Ala), rs1554840836, ClinGen CA377886429, ClinVar RCV000628504, TOPMed rs1554840836, AlphaMissense 0.73, MetaLR 0.43, Uncertain significance, Gorlin syndrome; Medulloblastoma
- P31L (p.Pro31Leu), rs2135598089, ClinGen CA377886437, ClinVar RCV001987705, ClinVar RCV002370593, REVEL 0.73, CADD 29.50, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- P31S (p.Pro31Ser), rs1554840836, ClinGen CA377886430, ClinVar RCV001359421, ClinVar RCV005503115, REVEL 0.59, AlphaMissense 0.73, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P31T (p.Pro31Thr), rs1554840836, ClinGen CA377886432, ClinVar RCV001343977, ClinVar RCV004036412, REVEL 0.67, AlphaMissense 0.73, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- P31P (p.Pro31Pro), gnomAD 10-102504245-C-G, CADD 14.90
- P32A (p.Pro32Ala), Ensembl rs2135598097, Uncertain significance, Hereditary cancer-predisposing syndrome
- P32L (p.Pro32Leu), rs2135598107, ClinGen CA377886448, ClinVar RCV001998240, ClinVar RCV004671585, AlphaMissense 0.34, MetaLR 0.39, Uncertain significance, Hereditary cancer-predisposing syndrome; Gorlin syndrome; Medulloblastoma
- P32Q (p.Pro32Gln), Ensembl rs2135598107, Uncertain significance, Hereditary cancer-predisposing syndrome
- P32R (p.Pro32Arg), Ensembl rs2135598107, Uncertain significance
- P32P (p.Pro32Pro), rs1483435746, gnomAD 10-102504248-G-A, CADD 13.70
- G33A (p.Gly33Ala), rs1391787041, ClinGen CA377886458, ClinVar RCV001019877, ClinVar RCV001370651, REVEL 0.95, CADD 29.90, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- G33R (p.Gly33Arg), Ensembl rs2135598136
- G33G (p.Gly33Gly), rs2135598153, gnomAD 10-102504251-A-C, CADD 15.90
- H35P (p.His35Pro), Ensembl rs2062292023, Uncertain significance
- H35Q (p.His35Gln), ExAC rs756766794, TOPMed rs756766794, gnomAD rs756766794, Uncertain significance, Gorlin syndrome; Medulloblastoma
- H35R (p.His35Arg), rs2062292023, ClinGen CA377886478, ClinVar RCV001309570, Ensembl rs2062292023, REVEL 0.27, CADD 23.10, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- H35Y (p.His35Tyr), rs2135598180, ClinGen CA377886474, cosmic curated COSV10528, ClinVar RCV002389605, REVEL 0.38, CADD 23.20, Uncertain significance, Gorlin syndrome; Medulloblastoma; not provided
- H35H (p.His35His), rs756766794, gnomAD 10-102504257-C-T, CADD 14.10
- A36P (p.Ala36Pro), Ensembl rs2135598210, Uncertain significance
- A36T (p.Ala36Thr), rs2135598210, ClinGen CA377886490, ClinVar RCV002298398, ClinVar RCV005742435, AlphaMissense 0.36, MetaLR 0.59, Uncertain significance, Medulloblastoma; Gorlin syndrome; Hereditary cancer-predisposing syndrome
- A36V (p.Ala36Val), rs566714720, ClinGen CA5667593, ClinVar RCV000228401, ClinVar RCV001009837, REVEL 0.67, CADD 24.30, Uncertain significance, Gorlin syndrome; Medulloblastoma; Hereditary cancer-predisposing syndrome
- A36G (p.Ala36Gly), gnomAD 10-102504259-C-G, REVEL 0.39, CADD 23.10
- I37L (p.Ile37Leu), rs745793517, ClinGen CA377886497, ClinVar RCV003177396, ExAC rs745793517, AlphaMissense 0.28, MetaLR 0.32, Uncertain significance, Hereditary cancer-predisposing syndrome
- I37N (p.Ile37Asn), rs2544831254, ClinGen CA377886501, ClinVar RCV002428957, Uncertain significance, Hereditary cancer-predisposing syndrome
- I37V (p.Ile37Val), rs745793517, ClinGen CA5667594, ClinVar RCV001057455, ClinVar RCV002451239, REVEL 0.48, AlphaMissense 0.28, Conflicting interpretations, Hereditary cancer-predisposing syndrome; Familial meningioma; Gorlin syndrome
Public SUFU analysis runs
- SUFU analysis run — SUFU (1,156 variants) — completed 2026-08-19